Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Undervalued stock
View:
Post by Infinity on Jan 17, 2022 6:42pm

Undervalued stock

Just a quick thought to hi-light the timeline projected by Theralase Technology in their September.   News Release.  The company is targeting mid 2022 for BTD and 2024-2025 for collaboration with big pharma to commercialise on a Global scale.   

Any Thoughts?
Comment by Infinity on Jan 17, 2022 6:45pm
I was refering to their presentation during their Sept news release, specifically slide 13.
Comment by floatinketucky on Jan 17, 2022 6:55pm
Yeah. That timeline was set by Shawn. The most conservative agent/mole player around but not around theralase anymore. Theralase® Announces Leadership Reorganization Toronto, Ontario – November 15, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinic... __________________________________________________________ November 29 ...more  
Comment by floatinketucky on Jan 17, 2022 6:57pm
"I am honored to return as the Interim CEO for the Company, as the Company realigns its executive management team to focus on the Company’s primary objective of commercialization of its ACT technology, which, if successful, will ultimately deliver shareholder value." Dr Arkady Mandel Interim CEO & CSO, Theralase® Nov 29, 2021 https://theralase.com/wp-content/uploads/2021/11/3Q ...more  
Comment by robertshaw on Jan 17, 2022 7:27pm
BTD maybe within 2 months instead of mid 2022....
Comment by Sunvalley on Jan 17, 2022 8:28pm
In my opinion , this little company will be scooped up by some large entity long before 2024 -2025 rolls around.. That is if the recovery numbers remain good of course. Big P will step in and take over the whole shebang as they do not like to share the wealth ,so to speak. 
Comment by Pandora on Jan 18, 2022 12:11am
At my age that may be the best thing  -- for me anyway.
Comment by Infinity on Jan 18, 2022 4:57am
Sunvalley,  agreed that every big pharma would like to buy  a smaller company outright, rather than in partnership.  However, please keep in mind, this is not just any small company.  TLT has the "rights" to develop this PDT 1433.  PDT has been proven at different levels to increase the survival rate and or cure NMIBC completely.  This is nothing short of ...more  
Comment by Sunvalley on Jan 18, 2022 7:16am
Good morning Infinity. Thank you for your post. You have brought up some excellent points. Well said.
Theralase Technologies Inc.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250